Drugs / Bebtelovimab
Bebtelovimab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04634409 | Oct 2020 → Jul 2021 | COVID-19 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04427501 | Jun 2020 → Feb 2023 | COVID-19 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04790786 | Mar 2021 → Jun 2022 | COVID-19 | Erin McCreary | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bebtelovimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04790786 ↗ |
| Known as | LY-CoV1404 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802210 ↗ |
| Known as | LY3853113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04427501 ↗ |
| Modality | Monoclonal antibody | “The monoclonal antibody of bebtelovimab” NCT04790786 ↗ |
| Route | Intravenous | “Administered IV” NCT04427501 ↗ |